Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome

Completed · Phase 2 · Has a placebo group

Conditions studied: Alagille Syndrome

In brief

The study is a randomized, double-blind, placebo-controlled study in children with Alagille Syndrome (ALGS). The study will investigate the effects of LUM001, compared to placebo, on pruritus, serum bile acids, liver enzymes, and other biochemical markers in patients with ALGS.

Key facts

Study ID
NCT02057692
Run by
Mirum Pharmaceuticals, Inc.
People needed
37
Starts
2014-11-24
Expected to finish
2016-11-16
Last updated by the study team
2019-03-26

Who can join

Age: 1 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.